| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.3 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.3 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.062 | 0.3 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.3 |